Jade Biosciences (NASDAQ:JBIO) Earns “Buy” Rating from HC Wainwright

Jade Biosciences (NASDAQ:JBIO)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a $55.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 292.66% from the company’s current price.

Other equities analysts also recently issued reports about the stock. BTIG Research increased their price objective on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. UBS Group started coverage on Jade Biosciences in a report on Monday, June 15th. They set a “buy” rating and a $45.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a research note on Tuesday, August 11th. Wedbush reiterated an “outperform” rating and set a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Jade Biosciences has a consensus rating of “Moderate Buy” and an average price target of $51.75.

Jade Biosciences Stock Down 1.2%

NASDAQ JBIO opened at $14.01 on Thursday. The firm’s 50 day moving average is $19.69 and its 200-day moving average is $19.74. The company has a market capitalization of $890.85 million, a PE ratio of -7.28 and a beta of 1.45. Jade Biosciences has a 12-month low of $8.16 and a 12-month high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, sell-side analysts expect that Jade Biosciences will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in JBIO. Y Intercept Hong Kong Ltd bought a new stake in Jade Biosciences in the 1st quarter valued at $353,000. Quantinno Capital Management LP boosted its position in Jade Biosciences by 3.6% during the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after purchasing an additional 1,059 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Jade Biosciences in the second quarter valued at $503,000. Bank of America Corp DE raised its position in shares of Jade Biosciences by 2.9% in the first quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after purchasing an additional 1,086 shares during the period. Finally, 9823 Capital L.P. bought a new position in shares of Jade Biosciences in the fourth quarter valued at about $821,000.

Jade Biosciences News Summary

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $55 price target, implying approximately 291.5% upside from the referenced $14.05 share price. The target signals substantial analyst confidence in Jade’s pipeline and could improve investor sentiment. Benzinga analyst rating report
• Positive Sentiment: Jade reported preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody being developed for dermatomyositis. The candidate showed selective, high-affinity IFN-β binding and greater functional potency than the dazukibart comparator in disease-relevant human cells. Jade Biosciences JADE301 preclinical data announcement
• Positive Sentiment: In non-human primates, subcutaneous JADE301 demonstrated an approximately 25-day half-life, predictable distribution into muscle and good tolerability across tested doses. These characteristics could support less frequent dosing and a differentiated product profile if confirmed clinically. Jade Biosciences advances JADE301 toward Phase 1
• Neutral Sentiment: Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. The clinical timeline provides a near-term catalyst, but meaningful efficacy and safety validation remain ahead. Jade Biosciences JADE301 announcement
• Negative Sentiment: The data are preclinical and do not establish that JADE301 will benefit patients or succeed in clinical trials. With shares below their 50-day and 200-day moving averages, investors may remain sensitive to development delays, trial setbacks and future financing needs.

Jade Biosciences Company Profile

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.